Ambulatory Patient Group

Lumos Pharma to Participate in World Orphan Drug Congress USA

Retrieved on: 
Monday, May 22, 2023
LUMO, Ambulatory Patient Group, CSO, Doctor of Philosophy, Congress, CBO, Drug development, AM, FDA, Pharmaceutical industry

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that management will participate in panel discussions at the World Orphan Drug Congress USA 2023 , held in Washington, D.C., May 23-25, 2023.

Key Points: 
  • AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that management will participate in panel discussions at the World Orphan Drug Congress USA 2023 , held in Washington, D.C., May 23-25, 2023.
  • John McKew, PhD, the Company’s President and Chief Scientific Officer, and Aaron Schuchart, its Chief Business Officer, will be participating in panel discussions as follows:
    May 24th, 4:20-5:00 PM ET - Patient Focused Drug Development - Best Practices on Patient Group and Drug Developer Interaction With FDA, John McKew, PhD, President & CSO
    May 25th, 11:10-11:50 AM ET –Partnering in The Rare Disease Space – Industry Perspectives, Aaron Schuchart, CBO

The Corporate Reputation of Pharma Companies in Canada, 2021-2022: The Patient Perspective - The Views of 124 Patient Groups - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Pharmaceutical, COVID-19, Reputation, Fear, Government, Quality of life, Diagnosis, Ambulatory Patient Group, Boehringer Ingelheim, Patient, Research, Comment, Medicine, Excellent, Medical device, Animal, Health insurance, Pharmaceutical industry, Fine chemical, Pharma, Novartis, Pfizer

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Canada Edition - The Views of 124 Canadian Patient Groups" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Canada Edition - The Views of 124 Canadian Patient Groups" report has been added to ResearchAndMarkets.com's offering.
  • Patient groups responding to the 'Corporate Reputation of Pharma' survey are uniquely positioned to comment on the pharma industry's performance during the pandemic.
  • The 124 Canadian patient groups responding to the 2021 'Corporate Reputation' survey rated the pharma industry more favourably for corporate reputation than their predecessors in previous years.
  • 66% of 2021's respondent Canadian patient groups stated that the industry had an "Excellent" or "Good" corporate reputation, against 44% saying the same in 2020.

The Value of Patient Co-Creation in Clinical Trial Design, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 7, 2022
Patient, Chair, Industry, HV, Value, Safety, BK, Nielsen, Cros, Skovlunde, Food, Clinical trial, Medicine, PC, Patient advocacy, Ambulatory Patient Group, Accelerator, Medical device, Pharmaceutical industry, Medical imaging

TORONTO, Nov. 7, 2022 /PRNewswire-PRWeb/ -- Co-creation with patients is vital for effective clinical trial design. A study by Skovlund, PC, Nielsen, BK, Thaysen, HV et al. shows that, in clinical trials, "patient involvement can lead to improvements in design, selection of relevant outcome measures and effective recruitment of trial participants."

Key Points: 
  • In this free webinar, learn about the value of patient co-creation in clinical trial design and how patient involvement can improve trial design and clinical outcome measures.
  • For a medicine to be authorised, clinical efficacy and safety need to be established, usually through robust and relevant clinical trial data.
  • Register to learn the value of patient co-creation in clinical trial design and how patient involvement can improve trial design and clinical outcome measures.
  • For more information, or to register for this event, visit The Value of Patient Co-Creation in Clinical Trial Design .